Literature DB >> 9436654

Pituitary tumors: surgical and medical management.

P J Yeh1, J W Chen.   

Abstract

The pituitary gland has been termed the 'master gland' because of the myriad of hormones that emanate from it that are vital for normal homeostasis as well as growth and development. Primary tumors of this region are frequent and account for up to 10% of intracranial tumors. Pituitary tumors are monoclonal in origin, and may arise from any of the different cell types of the pituitary gland. Hence, these tumors may be manifest by their hormonal secretions. This may lead to profound and striking physiological changes attributable, for example, to prolactin, growth hormone, or ACTH excess. The central location of the pituitary gland also leads to characteristic compressive symptoms. This review will explore the clinical presentations of growth hormone, ACTH, and prolactin secreting tumors as well as the non-secreting pituitary tumors. Advances in neuroimaging and neuropharmacology have resulted in changes in our treatment of these tumors. Treatment modalities including surgical, medical, and radiation therapy will be addressed. The treatment of choice is dictated by the type of tumor and the nature of the excessive hormonal expression. Outcomes and efficacy of treatment are discussed.

Entities:  

Mesh:

Year:  1997        PMID: 9436654     DOI: 10.1016/s0960-7404(97)00008-x

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  13 in total

Review 1.  Diagnosis and Management of pituitary disease with focus on the role of Magnetic Resonance Imaging.

Authors:  Amit Mahajan; Richard A Bronen; Ali Y Mian; Sacit Bulent Omay; Dennis D Spencer; Silvio E Inzucchi
Journal:  Endocrine       Date:  2020-03-11       Impact factor: 3.633

2.  Transsphenoidal resection of sellar tumors using high-field intraoperative magnetic resonance imaging.

Authors:  Nicholas J Szerlip; Yi-Chen Zhang; Dimitris G Placantonakis; Marc Goldman; Kara B Colevas; David G Rubin; Eric J Kobylarz; Sasan Karimi; Monica Girotra; Viviane Tabar
Journal:  Skull Base       Date:  2011-07

3.  11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas.

Authors:  B N T Tang; M Levivier; M Heureux; D Wikler; N Massager; D Devriendt; P David; N Dumarey; B Corvilain; S Goldman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-15       Impact factor: 9.236

Review 4.  Classification of pituitary adenomas.

Authors:  K Kovacs; E Horvath; S Vidal
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

5.  Craniocaudal extension as an indication of surgical outcome in transsphenoidal surgery for pituitary adenomas.

Authors:  Ossama Hamid; Adel El Hakim; Hossam El Husseiny; Lobna El Fiky; Sherif Kamel
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2011-11-27

Review 6.  Pituitary adenomas: historical perspective, surgical management and future directions.

Authors:  Debebe Theodros; Mira Patel; Jacob Ruzevick; Michael Lim; Chetan Bettegowda
Journal:  CNS Oncol       Date:  2015-10-26

Review 7.  Pituitary Adenomas: From Diagnosis to Therapeutics.

Authors:  Samridhi Banskota; David C Adamson
Journal:  Biomedicines       Date:  2021-04-30

8.  Visual Fields at Presentation and after Trans-sphenoidal Resection of Pituitary Adenomas.

Authors:  Renu Dhasmana; Ramesh C Nagpal; Rahul Sharma; Krishan K Bansal; Harsh Bahadur
Journal:  J Ophthalmic Vis Res       Date:  2011-07

9.  MRI image characteristics of materials implanted at sellar region after transsphenoidal resection of pituitary tumours.

Authors:  Joanna Bladowska; Grażyna Bednarek-Tupikowska; Violetta Sokolska; Roman Badowski; Krzysztof Moroń; Wiesław Bonicki; Marek Sąsiadek
Journal:  Pol J Radiol       Date:  2010-04

10.  Selective use of peri-operative steroids in pituitary tumor surgery: escape from dogma.

Authors:  Jacqueline Regan; Joseph Watson
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-18       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.